Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Avinger, Inc.

Avinger Announces Filing of 510(k) Submission for Tigereye ST Image-Guided CTO Crossing System
From Avinger, Inc.
Via AccessWire
Exposures Product Safety
Tickers AVGR
Avinger Expands International Presence with First Commercial Shipment to Chile
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC 2022
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Key Opinion Leader Presentation and Live Case at Vascular Conferences in Germany
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Reports First Quarter 2022 Results
From Avinger, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers AVGR
Avinger to Announce First Quarter 2022 Results on May 10
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Full Commercial Launch of Lightbox 3
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Issuance of Three New U.S. Patents in March 2022
From Avinger, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers AVGR
Avinger Regains Compliance with Nasdaq Listing Requirements
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Reports Fourth Quarter and Year End 2021 Results
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger to Announce Full-Year 2021 Results on March 22
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger to Effect One-for-Twenty Reverse Stock Split
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Expands Lightbox 3 First Case Experience
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Successful Completion of First Cases with the Lightbox 3 Next Generation Imaging Console
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Closing of $7.6 Million Registered Direct Offering
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces $7.6 Million Registered Direct Offering
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces FDA Clearance of Pantheris for the Treatment of In-Stent Restenosis
From Avinger, Inc.
Via AccessWire
Exposures Product Safety
Tickers AVGR
Avinger Reports Third Quarter 2021 Financial Results
From Avinger, Inc.
Via AccessWire
Exposures COVID-19
Tickers AVGR
Avinger to Announce Third Quarter Results on November 11, 2021
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
From Avinger, Inc.
Via AccessWire
Exposures Product Safety
Tickers AVGR
Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger OCT-Guided Technologies Featured at AMP 2021
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Reports Second Quarter 2021 Financial Results
From Avinger, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers AVGR
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger to Announce Second Quarter 2021 Results on August 10, 2021
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication
From Avinger, Inc.
Via AccessWire
Exposures Product Safety
Tickers AVGR
Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germany
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
From Avinger, Inc.
Via AccessWire
Tickers AVGR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.